These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [The characteristics of infectious immunosuppression in patients with benign subleukemic myelosis]. Guseva SA Lik Sprava; 1995; (7-8):32-6. PubMed ID: 8846368 [TBL] [Abstract][Full Text] [Related]
5. Opportunistic infection in children. II. In the compromised host. Feigin RD; Shearer WT J Pediatr; 1975 Nov; 87(5):677-94. PubMed ID: 1102640 [No Abstract] [Full Text] [Related]
6. Necroptotic death signaling: evolution, mechanisms and disease relevance. Vince JE Immunol Cell Biol; 2017 Feb; 95(2):129-130. PubMed ID: 28194028 [No Abstract] [Full Text] [Related]
9. Complications of the myeloproliferative system: infection and sepsis. Ellerhorst-Ryan JM Semin Oncol Nurs; 1985 Nov; 1(4):244-50. PubMed ID: 3854235 [No Abstract] [Full Text] [Related]
10. Current understanding of fever and host immunity. Alqahtani M; Mukundan D Curr Opin Pediatr; 2011 Feb; 23(1):115-20. PubMed ID: 21191298 [TBL] [Abstract][Full Text] [Related]
11. Contrasuppression, class I antigens, and cancer immunity. Green DR; Gershon RK Haematol Blood Transfus; 1983; 28():479-85. PubMed ID: 6602750 [No Abstract] [Full Text] [Related]
12. The role of cellular and humoral factors in infections. Neu HC Clin Haematol; 1976 Jun; 5(2):449-65. PubMed ID: 780033 [No Abstract] [Full Text] [Related]
13. [Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)]. Ivanov VT; Andronova TM; Nesmeianov VA; Pinegin BV; Ledger P; Bomford R; Khaitov RM Klin Med (Mosk); 1997; 75(3):11-5. PubMed ID: 9229604 [No Abstract] [Full Text] [Related]
14. Evolution of innate immune sensors and responses during immune disorders and immunization against microbial infection. Kumar H Int Rev Immunol; 2018; 37(5):215-216. PubMed ID: 30418071 [No Abstract] [Full Text] [Related]